The use of IgA therapeutic antibodies enhances neutrophil-mediated ADCC of cancer cells compared to using IgG antibodies (54, 55), which could be in part due to the production of cytokines, such as IL-8, by the neutrophils. Here, CXCL8 is linked to cancer.